GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xiamen Amoytop Biotech Co Ltd (SHSE:688278) » Definitions » Gross Profit

Xiamen Amoytop Biotech Co (SHSE:688278) Gross Profit : ¥2,419 Mil (TTM As of Sep. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Xiamen Amoytop Biotech Co Gross Profit?

Xiamen Amoytop Biotech Co's gross profit for the three months ended in Sep. 2024 was ¥714 Mil. Xiamen Amoytop Biotech Co's gross profit for the trailing twelve months (TTM) ended in Sep. 2024 was ¥2,419 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Xiamen Amoytop Biotech Co's gross profit for the three months ended in Sep. 2024 was ¥714 Mil. Xiamen Amoytop Biotech Co's Revenue for the three months ended in Sep. 2024 was ¥765 Mil. Therefore, Xiamen Amoytop Biotech Co's Gross Margin % for the quarter that ended in Sep. 2024 was 93.34%.

Xiamen Amoytop Biotech Co had a gross margin of 93.34% for the quarter that ended in Sep. 2024 => Durable competitive advantage

During the past 8 years, the highest Gross Margin % of Xiamen Amoytop Biotech Co was 93.33%. The lowest was 87.10%. And the median was 88.99%.


Xiamen Amoytop Biotech Co Gross Profit Historical Data

The historical data trend for Xiamen Amoytop Biotech Co's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xiamen Amoytop Biotech Co Gross Profit Chart

Xiamen Amoytop Biotech Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Profit
Get a 7-Day Free Trial 649.69 710.29 1,007.09 1,357.67 1,960.27

Xiamen Amoytop Biotech Co Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 526.42 594.10 507.54 603.30 713.94

Competitive Comparison of Xiamen Amoytop Biotech Co's Gross Profit

For the Biotechnology subindustry, Xiamen Amoytop Biotech Co's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Xiamen Amoytop Biotech Co's Gross Profit Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Xiamen Amoytop Biotech Co's Gross Profit distribution charts can be found below:

* The bar in red indicates where Xiamen Amoytop Biotech Co's Gross Profit falls into.



Xiamen Amoytop Biotech Co Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Xiamen Amoytop Biotech Co's Gross Profit for the fiscal year that ended in Dec. 2023 is calculated as

Gross Profit (A: Dec. 2023 )=Revenue - Cost of Goods Sold
=2100.323 - 140.054
=1,960

Xiamen Amoytop Biotech Co's Gross Profit for the quarter that ended in Sep. 2024 is calculated as

Gross Profit (Q: Sep. 2024 )=Revenue - Cost of Goods Sold
=764.897 - 50.962
=714

Gross Profit for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥2,419 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

Xiamen Amoytop Biotech Co's Gross Margin % for the quarter that ended in Sep. 2024 is calculated as

Gross Margin % (Q: Sep. 2024 )=Gross Profit (Q: Sep. 2024 ) / Revenue (Q: Sep. 2024 )
=(Revenue - Cost of Goods Sold) / Revenue
=714 / 764.897
=93.34 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Xiamen Amoytop Biotech Co  (SHSE:688278) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Xiamen Amoytop Biotech Co had a gross margin of 93.34% for the quarter that ended in Sep. 2024 => Durable competitive advantage


Xiamen Amoytop Biotech Co Gross Profit Related Terms

Thank you for viewing the detailed overview of Xiamen Amoytop Biotech Co's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Xiamen Amoytop Biotech Co Business Description

Traded in Other Exchanges
N/A
Address
No.330 Wengjiao Road, Xinyang Industry Zone of Haicang, Fujian, Xiamen, CHN, 361022
Xiamen Amoytop Biotech Co Ltd operates as a drug development company. The Company develops and sells protein drugs, interferon drugs, and other products.
Executives
Lan Chun Director
Wang Jun Ye Director

Xiamen Amoytop Biotech Co Headlines

No Headlines